Trial Profile
A Single Dose Study to Investigate the Pharmacokinetics of MK4305 in Patients With Hepatic Insufficiency
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Suvorexant (Primary)
- Indications Insomnia
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme Corp.
- 26 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 May 2010 Planned end date changed from 1 Apr 2010 to 1 Jun 2010 as reported by ClinicalTrials.gov.
- 18 Feb 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.